- May 9, 2013 BioCryst to Present at Two Upcoming Investor Conferences
- May 7, 2013 BioCryst Provides Corporate Update and Reports First Quarter 2013 Financial Results
- Apr 23, 2013 BioCryst to Announce First Quarter 2013 Financial Results May 7
- Apr 16, 2013 BioCryst Pharmaceuticals Completes Peramivir Type C Meeting
- Apr 1, 2013 BioCryst Pharmaceuticals Provides Update Regarding Peramivir
- Mar 25, 2013 BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX4161 for the Treatment of Hereditary Angioedema
- Feb 19, 2013 BioCryst Reports Fourth Quarter and Full Year 2012 Financial Results
- Feb 5, 2013 BioCryst to Announce Fourth Quarter & 2012 Financial Results on February 19, 2013
- Jan 2, 2013 BioCryst to Present at J.P. Morgan Healthcare Conference
- Dec 7, 2012 BioCryst Pharmaceuticals Announces Focused Corporate Strategy and Restructuring
- Nov 30, 2012 BioCryst Pharmaceuticals and Presidio Pharmaceuticals Mutually Terminate Merger Transaction
- Nov 12, 2012 BioCryst Broad-Spectrum Antiviral BCX4430 Highly Effective against Yellow Fever in a Preclinical Disease Model
- Nov 8, 2012 BioCryst Provides Corporate Update and Reports Third Quarter 2012 Financial Results
- Nov 7, 2012 BioCryst Announces Outcome from the Peramivir Phase 3 Interim Analysis
- Nov 1, 2012 BioCryst to Report Third Quarter 2012 Financial Results on November 8, 2012
- Oct 30, 2012 BioCryst Provides Update Regarding BCX5191 Development Plan Following Discussion With FDA
- Oct 18, 2012 BioCryst Pharmaceuticals and Presidio Pharmaceuticals to Merge
- Aug 2, 2012 BioCryst Provides Corporate Update and Reports Second Quarter 2012 Financial Results
- Jul 24, 2012 BioCryst Announces Positive Results from Two Ulodesine Phase 2 Trials in Patients with Gout
- Jul 19, 2012 BioCryst to Report Second Quarter 2012 Financial Results on August 2, 2012
BCRX - NASDAQ